LCAT in Cancer Biology: Embracing Epigenetic Regulation, Immune Interactions, and Therapeutic Implications
International Journal of Molecular Sciences · 10.02.2025 · 26 (4) · 1453
DOI: 10.3390/ijms26041453 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.02.2025. Verfasst von Manzhi Gao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Aerospace Hygiene, School of Aerospace Medicine, Air Force Medical University, Xi'an 710032, China. Hauptthemen laut MEDLINE: Neoplasms, Epigenesis, Genetic, Phosphatidylcholine-Sterol O-Acyltransferase. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shaanxi Provincial Key Research and Development Program.
Abstract (Originalsprache)
Lecithin cholesterol acyltransferase (LCAT) is a crucial enzyme in high-density lipoprotein (HDL) metabolism that is often dysregulated in cancers, affecting tumor growth and therapy response. We extensively studied LCAT expression in various malignancies, linking it to clinical outcomes and genetic/epigenetic alterations. We analyzed LCAT expression in multiple cancers and used the Cox regression model to correlate it with patient survival metrics, including overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI). We also examined the copy number variations (CNVs), single-nucleotide variations (SNVs), DNA methylation, and N6-methyladenosine (m6A) modifications of LCAT and their connections to tumor immune responses and drug sensitivity. LCAT expression varies among cancers and correlates with patient outcomes. Low expression is linked to poor prognosis in low-grade glioma (LGG) and liver hepatocellular carcinoma (LIHC), while high expression is associated with better outcomes in adrenocortical carcinoma (ACC) and colon adenocarcinoma (COAD). In kidney renal papillary cell carcinoma (KIRP) and uterine corpus endometrial carcinoma (UCEC), LCAT CNV and methylation levels are prognostic markers. LCAT interacts with m6A modifiers and immune molecules, suggesting a role in immune evasion and as a biomarker for immunotherapy response. LCAT expression correlates with chemotherapeutic drug IC50 values, indicating potential for predicting treatment response. In ACC and COAD, LCAT may promote tumor growth, while in LGG and LIHC, it may inhibit progression. LCAT expression and activity regulation could be a new cancer therapy target. As a key molecule linking lipid metabolism, immune modulation, and tumor progression, the potential of LCAT in cancer therapy is significant. Our findings provide new insights into the role of LCAT in cancer biology and support the development of personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Aerospace Hygiene, School of Aerospace Medicine, Air Force Medical University, Xi'an 710032, China.
- Key Laboratory of Aerospace Medicine of Ministry of Education, Air Force Medical University, Xi'an 710032, China.
ORCID-Profile: Manzhi Gao, Wenlan Wang
Förderung
- Shaanxi Provincial Key Research and Development Program
Zitieren
APA
Gao, M., Zhang, W., Li, X., Li, S., Wang, W., & Han, P. (2025). LCAT in Cancer Biology: Embracing Epigenetic Regulation, Immune Interactions, and Therapeutic Implications. International Journal of Molecular Sciences, 26(4), 1453. https://doi.org/10.3390/ijms26041453
Vancouver
Gao M, Zhang W, Li X, Li S, Wang W, Han P. LCAT in Cancer Biology: Embracing Epigenetic Regulation, Immune Interactions, and Therapeutic Implications. International Journal of Molecular Sciences. 2025;26(4):1453. doi:10.3390/ijms26041453
BibTeX
@article{Gao2025,
author = {Gao, Manzhi and Zhang, Wentian and Li, Xinxin and Li, Sumin and Wang, Wenlan and Han, Peijun},
title = {LCAT in Cancer Biology: Embracing Epigenetic Regulation, Immune Interactions, and Therapeutic Implications},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {4},
pages = {1453},
doi = {10.3390/ijms26041453}
}
EUVIMED